Noesis Capital Mangement Corp Has $1.38 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Noesis Capital Mangement Corp grew its holdings in Johnson & Johnson (NYSE:JNJ) by 5.1% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,492 shares of the company’s stock after purchasing an additional 410 shares during the period. Noesis Capital Mangement Corp’s holdings in Johnson & Johnson were worth $1,376,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in JNJ. Public Sector Pension Investment Board grew its position in Johnson & Johnson by 470.2% in the third quarter. Public Sector Pension Investment Board now owns 524,839 shares of the company’s stock valued at $85,055,000 after purchasing an additional 432,800 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Johnson & Johnson by 0.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,248,528 shares of the company’s stock worth $202,336,000 after buying an additional 5,094 shares during the last quarter. BBR Partners LLC grew its holdings in shares of Johnson & Johnson by 13.3% in the 3rd quarter. BBR Partners LLC now owns 27,474 shares of the company’s stock valued at $4,452,000 after acquiring an additional 3,215 shares in the last quarter. Bell Investment Advisors Inc increased its position in shares of Johnson & Johnson by 28.3% in the third quarter. Bell Investment Advisors Inc now owns 757 shares of the company’s stock valued at $123,000 after acquiring an additional 167 shares during the last quarter. Finally, RPg Family Wealth Advisory LLC bought a new stake in Johnson & Johnson during the third quarter worth about $35,000. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent analyst reports. Guggenheim boosted their price target on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. Morgan Stanley boosted their target price on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Wolfe Research began coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 price target for the company. Royal Bank of Canada upped their target price on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a report on Wednesday, October 16th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $175.94.

Insider Activity

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. This trade represents a 22.90 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $155.39 on Thursday. The business’s 50 day moving average is $159.52 and its 200-day moving average is $156.38. The firm has a market cap of $374.12 billion, a P/E ratio of 22.49, a price-to-earnings-growth ratio of 2.77 and a beta of 0.53. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. During the same quarter last year, the firm earned $2.66 earnings per share. The company’s revenue was up 5.2% on a year-over-year basis. Equities research analysts predict that Johnson & Johnson will post 9.93 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 annualized dividend and a dividend yield of 3.19%. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.